AI-assembled from public SEC filings
Food and beverage staples peer review
Descriptive comparison assembled from public SEC filings and verified companyfacts.
This feature-specific review is assembled from a frozen evidence pack of public SEC filing quotes and verified SEC companyfacts numbers. It is descriptive only and makes no judgment about which company is better. It is not a rating, recommendation, endorsement, forecast, or investment advice. Figures are as of their cited filing dates.
Methodology
The cluster is selected mechanically from public SEC SIC 2080 and 2000s food-manufacturing companies already present in grepcent's processed universe, spanning beverage-led KO/PEP and packaged-food peers. Missing requested tickers are not fabricated. The review publishes no proprietary index-membership labels.
Verified Quantitative Matrix
Numbers are templated from frozen SEC companyfacts-derived facts already verified by grepcent. Fiscal periods and filing dates are shown in each cell; code-computed comparisons below only use calendar-aligned periods.
| Metric | KO | PEP | MDLZ | GIS | KHC | HSY | CAG | CPB |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47,941,000,000 source · NUM_KO_REVENUE_FY2025 | 93,925,000,000 source · NUM_PEP_REVENUE_FY2025 | 38,537,000,000 source · NUM_MDLZ_REVENUE_FY2025 | 19,486,600,000 source · NUM_GIS_REVENUE_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 24,942,000,000 source · NUM_KHC_REVENUE_FY2025 | 11,692,576,000 source · NUM_HSY_REVENUE_FY2025 | 11,612,800,000 source · NUM_CAG_REVENUE_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 10,253,000,000 source · NUM_CPB_REVENUE_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Gross margin | 61.63% source · NUM_KO_GROSS_MARGIN_FY2025 | 54.15% source · NUM_PEP_GROSS_MARGIN_FY2025 | 28.38% source · NUM_MDLZ_GROSS_MARGIN_FY2025 | 34.55% source · NUM_GIS_GROSS_MARGIN_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 33.31% source · NUM_KHC_GROSS_MARGIN_FY2025 | 33.55% source · NUM_HSY_GROSS_MARGIN_FY2025 | 25.86% source · NUM_CAG_GROSS_MARGIN_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 30.42% source · NUM_CPB_GROSS_MARGIN_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Operating margin | 28.71% source · NUM_KO_OPERATING_MARGIN_FY2025 | 12.24% source · NUM_PEP_OPERATING_MARGIN_FY2025 | 9.21% source · NUM_MDLZ_OPERATING_MARGIN_FY2025 | 16.96% source · NUM_GIS_OPERATING_MARGIN_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | -18.72% source · NUM_KHC_OPERATING_MARGIN_FY2025 | 12.33% source · NUM_HSY_OPERATING_MARGIN_FY2025 | 11.75% source · NUM_CAG_OPERATING_MARGIN_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 10.96% source · NUM_CPB_OPERATING_MARGIN_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Net margin | 27.34% source · NUM_KO_NET_MARGIN_FY2025 | 8.77% source · NUM_PEP_NET_MARGIN_FY2025 | 6.36% source · NUM_MDLZ_NET_MARGIN_FY2025 | 11.78% source · NUM_GIS_NET_MARGIN_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | -23.44% source · NUM_KHC_NET_MARGIN_FY2025 | 7.55% source · NUM_HSY_NET_MARGIN_FY2025 | 9.92% source · NUM_CAG_NET_MARGIN_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 5.87% source · NUM_CPB_NET_MARGIN_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Capital expenditures | 2,112,000,000 source · NUM_KO_CAPEX_FY2025 | 4,415,000,000 source · NUM_PEP_CAPEX_FY2025 | 1,279,000,000 source · NUM_MDLZ_CAPEX_FY2025 | 625,300,000 source · NUM_GIS_CAPEX_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 801,000,000 source · NUM_KHC_CAPEX_FY2025 | 454,622,000 source · NUM_HSY_CAPEX_FY2025 | 389,300,000 source · NUM_CAG_CAPEX_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 426,000,000 source · NUM_CPB_CAPEX_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Free cash flow | 5,296,000,000 source · NUM_KO_FREE_CASH_FLOW_FY2025 | 7,672,000,000 source · NUM_PEP_FREE_CASH_FLOW_FY2025 | 3,235,000,000 source · NUM_MDLZ_FREE_CASH_FLOW_FY2025 | 2,292,900,000 source · NUM_GIS_FREE_CASH_FLOW_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 3,661,000,000 source · NUM_KHC_FREE_CASH_FLOW_FY2025 | 1,822,745,000 source · NUM_HSY_FREE_CASH_FLOW_FY2025 | 1,302,600,000 source · NUM_CAG_FREE_CASH_FLOW_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 705,000,000 source · NUM_CPB_FREE_CASH_FLOW_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Dividends paid | 8,779,000,000 source · NUM_KO_DIVIDENDS_PAID_FY2025 | 7,638,000,000 source · NUM_PEP_DIVIDENDS_PAID_FY2025 | 2,487,000,000 source · NUM_MDLZ_DIVIDENDS_PAID_FY2025 | 1,338,700,000 source · NUM_GIS_DIVIDENDS_PAID_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 1,898,000,000 source · NUM_KHC_DIVIDENDS_PAID_FY2025 | 1,085,296,000 source · NUM_HSY_DIVIDENDS_PAID_FY2025 | 669,200,000 source · NUM_CAG_DIVIDENDS_PAID_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 459,000,000 source · NUM_CPB_DIVIDENDS_PAID_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Dividends / net income | 66.98% source · NUM_KO_PAYOUT_RATIO_FY2025 | 92.69% source · NUM_PEP_PAYOUT_RATIO_FY2025 | 101.47% source · NUM_MDLZ_PAYOUT_RATIO_FY2025 | 58.33% source · NUM_GIS_PAYOUT_RATIO_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | Not available. | 122.87% source · NUM_HSY_PAYOUT_RATIO_FY2025 | 58.07% source · NUM_CAG_PAYOUT_RATIO_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 76.25% source · NUM_CPB_PAYOUT_RATIO_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Liabilities / equity leverage | 2.26 source · NUM_KO_LIABILITIES_TO_EQUITY_FY2025 | 4.26 source · NUM_PEP_LIABILITIES_TO_EQUITY_FY2025 | 1.76 source · NUM_MDLZ_LIABILITIES_TO_EQUITY_FY2025 | 2.59 source · NUM_GIS_LIABILITIES_TO_EQUITY_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 0.96 source · NUM_KHC_LIABILITIES_TO_EQUITY_FY2025 | 1.96 source · NUM_HSY_LIABILITIES_TO_EQUITY_FY2025 | 1.34 source · NUM_CAG_LIABILITIES_TO_EQUITY_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 2.82 source · NUM_CPB_LIABILITIES_TO_EQUITY_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Cash and equivalents | 10,270,000,000 source · NUM_KO_CASH_FY2025 | 9,159,000,000 source · NUM_PEP_CASH_FY2025 | Not available. | 363,900,000 source · NUM_GIS_CASH_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 2,615,000,000 source · NUM_KHC_CASH_FY2025 | Not available. | 68,000,000 source · NUM_CAG_CASH_FY2025 Non-aligned period: 2025-Q2; row majority 2025-Q4. | 132,000,000 source · NUM_CPB_CASH_FY2025 Non-aligned period: 2025-Q3; row majority 2025-Q4. |
| Organic/volume growth | Quarantined: Only 0 of 8 companies have a verified fact; threshold is 3. | |||||||
Code-computed comparisons
- grepcent-computed gross margin range: range endpoints are MDLZ (28.38%) and KO (61.63%).
- grepcent-computed dividend payout range: range endpoints are KO (66.98%) and HSY (122.87%).
Narrative Matrix
| Dimension | KO | PEP | MDLZ | GIS | KHC | HSY | CAG | CPB |
|---|---|---|---|---|---|---|---|---|
| Business model | In its latest annual MD&A, KO describes this business model item. [FACT:Q_KO_BUSINESS_MODEL_1] We own or license and market numerous beverage brands, which we group into the following categories: Trademark Coca-Cola; sparkling flavors; water, sports, coffee and tea; juice, value-added dairy and plant-based beverages; and emerging beverages. company page · source filing · fact Q_KO_BUSINESS_MODEL_1 · filed 2026-02-20 | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | In its latest annual MD&A, CAG describes this business model item. [FACT:Q_CAG_BUSINESS_MODEL_1] Conagra’s brands include Birds Eye®, Duncan Hines®, Healthy Choice®, Marie Callender’s®, Reddi-wip®, Slim Jim®, Angie’s® BOOMCHICKAPOP®, and many more. company page · source filing · fact Q_CAG_BUSINESS_MODEL_1 · filed 2025-07-10 | Quarantined: no direct dimension-relevant quote survived the gate. |
| Geographic and customer exposure | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. |
| Capital allocation | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. |
| Stated strategy in filings | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. |
| Idiosyncratic risks in filings | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | In its latest annual MD&A, MDLZ describes this idiosyncratic risks in filings item. [FACT:Q_MDLZ_IDIOSYNCRATIC_RISKS_1] In February 2022, following the Russian military invasion of Ukraine, we stopped production and closed our facilities in Ukraine; since then we have taken steps to protect the safety of our employees and to restore operations at our two manufacturing facilities, which were significantly damaged in March 2022. company page · source filing · fact Q_MDLZ_IDIOSYNCRATIC_RISKS_1 · filed 2026-02-04 | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | In its latest annual MD&A, HSY describes this idiosyncratic risks in filings item. [FACT:Q_HSY_IDIOSYNCRATIC_RISKS_1] The decrease was partially offset by $372.1 million of higher costs, primarily driven by higher commodity costs from cocoa, higher supply chain costs, unfavorable mix and incremental business realignment costs. company page · source filing · fact Q_HSY_IDIOSYNCRATIC_RISKS_1 · filed 2026-02-17 | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. |
| Recent narrative change | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. | Quarantined: no direct dimension-relevant quote survived the gate. |
Gate summary
Quarantined quantitative rows
- organic_volume_growth: Only 0 of 8 companies have a verified fact; threshold is 3.
Quarantined dimensions
- geographic_customer_exposure: No verified cells survived the gate.
- capital_allocation: No verified cells survived the gate.
- stated_strategy: No verified cells survived the gate.
- recent_narrative_change: No verified cells survived the gate.
Quarantined cells
- PEP / business_model: No direct dimension-relevant quote survived the evidence gate.
- MDLZ / business_model: No direct dimension-relevant quote survived the evidence gate.
- GIS / business_model: No direct dimension-relevant quote survived the evidence gate.
- KHC / business_model: No direct dimension-relevant quote survived the evidence gate.
- HSY / business_model: No direct dimension-relevant quote survived the evidence gate.
- CPB / business_model: No direct dimension-relevant quote survived the evidence gate.
- KO / geographic_customer_exposure: No direct dimension-relevant quote survived the evidence gate.
- PEP / geographic_customer_exposure: No direct dimension-relevant quote survived the evidence gate.
- MDLZ / geographic_customer_exposure: No direct dimension-relevant quote survived the evidence gate.
- GIS / geographic_customer_exposure: No direct dimension-relevant quote survived the evidence gate.
- KHC / geographic_customer_exposure: No direct dimension-relevant quote survived the evidence gate.
- HSY / geographic_customer_exposure: No direct dimension-relevant quote survived the evidence gate.
- CAG / geographic_customer_exposure: No direct dimension-relevant quote survived the evidence gate.
- CPB / geographic_customer_exposure: No direct dimension-relevant quote survived the evidence gate.
- KO / capital_allocation: No direct dimension-relevant quote survived the evidence gate.
- PEP / capital_allocation: No direct dimension-relevant quote survived the evidence gate.
- MDLZ / capital_allocation: No direct dimension-relevant quote survived the evidence gate.
- GIS / capital_allocation: No direct dimension-relevant quote survived the evidence gate.
- KHC / capital_allocation: No direct dimension-relevant quote survived the evidence gate.
- HSY / capital_allocation: No direct dimension-relevant quote survived the evidence gate.
- CAG / capital_allocation: No direct dimension-relevant quote survived the evidence gate.
- CPB / capital_allocation: No direct dimension-relevant quote survived the evidence gate.
- KO / stated_strategy: No direct dimension-relevant quote survived the evidence gate.
- PEP / stated_strategy: No direct dimension-relevant quote survived the evidence gate.